PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of a new generation of targeted treatments for cancer and immunologic diseases.
PDL BioPharma Completes Regular Quarterly Dividend Payment
PDL BioPharma Provides Fourth Quarter 2014 Revenue Guidance of $158 Million
PDL BioPharma Announces Conversion Rate Adjustments for Convertible Notes
PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics
PDL BioPharma Announces Successful Conclusion of Revenue Interest Agreement with AxoGen